Catalyst Pharmaceuticals (CPRX) director reports option exercise, sale

Rhea-AI Filing Summary

Catalyst Pharmaceuticals director Molly Harper reported exercising stock options and selling common shares of the company. On 12/12/2025, she exercised options to purchase 20,000 shares of common stock at an exercise price of $5.78 per share, converting them into common shares. She then sold common stock in several open-market transactions, including 15,527 shares at a weighted average price of $23.198, 4,473 shares at $23.734, and 6,746 shares at $23.06 per share. Following these transactions, she directly beneficially owned 2,360 shares of common stock and 128,497 options to purchase common stock. The sales were made on the open market for personal reasons and to help fund the option exercise, and were not due to any disagreement with the company.

Insider Trade Summary

Net Seller: 26,746 shares ($621,920)

Net Sell 5 txns

Insider Harper Molly

Role Director

Sold 26,746 shs ($622K)

Type	Security	Shares	Price	Value
Exercise	Options to purchase common stock	20,000	$0.00	--
Exercise	Common stock, par value $0.001 per share	20,000	$5.78	$116K
Sale	Common stock, par value $0.001 per share	15,527	$23.198	$360K
Sale	Common stock, par value $0.001 per share	4,473	$23.734	$106K
Sale	Common stock, par value $0.001 per share	6,746	$23.06	$156K

Holdings After Transaction: Options to purchase common stock — 128,497 shares (Direct); Common stock, par value $0.001 per share — 29,106 shares (Direct)

Footnotes (1)

1. Shares were sold on the open market for personal reasons and to fund the exercise price of the stock options, and not as a result of any disagreement with the Company. Represents a weighted average price for the shares sold. Shares were sold in a range between $22.67 and $23.67 per share. Represents a weighted average price for the shares sold. Shares were sold in a range between $23.67 and $23.82 per share. Options vested in three annual tranches beginning on June 29, 2022.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Harper Molly

(Last) (First) (Middle)

355 ALHAMBRA CIRCLE

SUITE 801

(Street)

CORAL GABLES FL 33134

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CATALYST PHARMACEUTICALS, INC. [ CPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock, par value $0.001 per share	12/12/2025		M		20,000	A	$5.78	29,106	D
Common stock, par value $0.001 per share	12/12/2025		S		15,527(1)	D	$23.198(2)	13,579	D
Common stock, par value $0.001 per share	12/12/2025		S		4,473(1)	D	$23.734(3)	9,106	D
Common stock, par value $0.001 per share	12/12/2025		S		6,746(1)	D	$23.06	2,360	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options to purchase common stock	$5.78	12/12/2025		M			20,000	(4)	06/29/2028	Common Stock	20,000	$0	128,497	D

Explanation of Responses:

1. Shares were sold on the open market for personal reasons and to fund the exercise price of the stock options, and not as a result of any disagreement with the Company.

2. Represents a weighted average price for the shares sold. Shares were sold in a range between $22.67 and $23.67 per share.

3. Represents a weighted average price for the shares sold. Shares were sold in a range between $23.67 and $23.82 per share.

4. Options vested in three annual tranches beginning on June 29, 2022.

	/s/ Molly Harper	12/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Catalyst Pharmaceuticals (CPRX) report?

The filing reports that director Molly Harper exercised stock options to acquire common shares of Catalyst Pharmaceuticals, Inc. (CPRX) and then sold portions of those shares in multiple open-market transactions.

How many Catalyst Pharmaceuticals (CPRX) stock options did Molly Harper exercise?

Molly Harper exercised 20,000 options to purchase Catalyst Pharmaceuticals common stock at an exercise price of $5.78 per share.

At what prices were Catalyst Pharmaceuticals (CPRX) shares sold by the director?

Shares were sold in several open-market trades, including 15,527 shares at a weighted average price of $23.198 per share, 4,473 shares at $23.734 per share, and 6,746 shares at $23.06 per share.

How many Catalyst Pharmaceuticals (CPRX) shares does Molly Harper own after the transactions?

After the reported transactions, Molly Harper directly beneficially owned 2,360 shares of Catalyst Pharmaceuticals common stock and 128,497 options to purchase additional shares.

Why did the Catalyst Pharmaceuticals (CPRX) director sell shares?

The filing states that the shares were sold on the open market for personal reasons and to fund the exercise price of the stock options, and not due to any disagreement with Catalyst Pharmaceuticals.

What is the role of the reporting person at Catalyst Pharmaceuticals (CPRX)?

The reporting person, Molly Harper, is identified as a director of Catalyst Pharmaceuticals, Inc.